Research graph
References from Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties. Local targets link to admitted publications; unresolved targets remain external evidence.
IUPHAR review: from foe to friend: repurposing glucagon to treat obesity and type 2 diabetes
10.1016/j.phrs.2025.108077 · 2026 · External reference
Baseline characteristics in the SYNCHRONIZE-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes
10.1111/dom.70263 · 2026 · External reference
Survodutide for treatment of obesity: baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE-1)
10.1111/dom.70196 · 2026 · External reference
Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation
10.1016/j.molmet.2026.102326 · 2026 · External reference
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2)
10.1002/oby.24184 · 2025 · External reference
Survodutide: a dual GLP-1/glucagon agonist reshaping cardiometabolic care
10.1097/crd.0000000000001062 · 2025 · External reference
Operationalising disease modification in obesity trials: a blueprint based on the SYNCHRONIZE-1 survodutide study
10.1111/dom.70407 · 2026 · External reference
Liver biopsy handling of metabolic-associated fatty liver disease (MAFLD): the Children’s Hospital of Eastern Ontario grossing protocol
10.1177/20420188241227766 · 2024 · External reference
NAFLD (MASLD)/NASH (MASH): does it bother to label at all? A comprehensive narrative review
10.3390/ijms25158462 · 2024 · External reference
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis
10.1016/j.jhep.2024.06.003 · 2024 · External reference
How to conduct a Bayesian network meta-analysis
10.3389/fvets.2020.00271 · 2020 · External reference
Efficacy and safety of GLP-1 receptor agonists, dual agonists, and Retatrutide for weight loss in adults with overweight or obesity: a Bayesian NMA
10.1002/oby.24360 · 2025 · External reference
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
10.1016/s0140-6736(23)01053-x · 2023 · External reference
Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy
10.1080/14656566.2023.2181074 · 2023 · External reference
The role of Tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of Type 2 diabetes: the SURPASS clinical trials
10.1007/s13300-020-00981-0 · 2021 · External reference
Unresolved reference
External reference
Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trial
2025 · External reference
GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials
10.1111/dom.16489 · 2025 · External reference
